Tazobactam is a penicillanic acid sulfone derivative and beta-lactamase inhibitor with antibacterial activity. Tazobactam was discovered by Dr. R.G. Micetech at the University of Alberta in 1982. Tazobactam contains a beta-lactam ring and irreversibly binds to beta-lactamase at or near its active site. This protects other beta-lactam antibiotics from beta-lactamase catalysis. This drug is used in conjunction with beta-lactamase susceptible penicillins to treat infections caused by beta-lactamase producing organisms.
Tazobactam alone showed an MIC of ≤ 8 mg/liter (range 2 to 32 mg/liter) against several Acinetobacter baumannii strains. Tazobactam in combination with piperacillin, successfully restored the activity of piperacillin against β-lactamase-producing bacteria. Tazobactam exhibited inhibitory activity and protected piperacillin against Richmond and Sykes types II, III, IV and V β-lactamases, staphylococcal penicillinase and extended-spectrum β-lactamases. Tazobactam showed species-specific activity against class I chromosomally-mediated enzymes.
TOKU-E offers two forms of tazobactam: tazobactam (T001) and tazobactam sodium (T031). Tazobactam is slightly soluble in aqueous solution (9.59 mg/mL). Tazobactam sodium is freely soluble in aqueous solution.
|Mechanism of Action||Tazobactam contains a beta-lactam ring that binds strongly to beta-lactamase at or near its activation site, thereby permanently inhibiting enzymatic activity. This action protects other beta-lactam antibiotics (penicillins, cephalosporins, etc.) from beta-lactamase catalysis, thereby enhancing their antibacterial activity.|
Tazobactam exhibits little useful antimicrobial activity, although weak activity against Acinetobacter spp. and Borrelia burgdorferi has been reported.
Tazobactam inhibits a wide range of β-lactamases, including the group 2 penicillinases from Staph. aureus, the TEM-1 and SHV-1 β-lactamases, many extended-spectrum enzymes, and the common group 2e cephalosporinases of B. fragilis. Against the group 1 cephalosporinases, activity is strongly influenced by the amount of enzyme produced. The inhibitor-resistant group 2br β-lactamases are poorly inhibited and group 3 metallo-β-lactamases are not inhibited at clinically useful levels. It is a poor inducer of β-lactamases of Gram-positive and Gram-negative organisms.
|Microbiology Applications||Tazobactam is often combined with the extended-spectrum β-lactam antibiotic piperacillin in the drug zosyn or Tazocin (piperacillin/tazobactam), used in infections due Pseudomonas aeruginosa. Tazobactam broadens the spectrum of piperacillin by making it effective against organisms that express β-lactamase and would normally degrade piperacillin.|
Craig, W.A., and Andes, D.R. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob. Agents Chemother. 57(4),1577-1582 (2013).
Jones, R.N., Pfaller, M.A., Fuchs, P.C., et al. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn. Microbiol. Infect. Dis. 12(6), 489-494 (1989).
|MIC||Escherichia coli (DH5α + pBC-OXA-46)| 4 － ?| 660| Escherichia coli (DH5α + pBC-SK)| 4 － ?| 660||